JDRF welcomes Disability Advisory Committee's recommendation that all Canadians needing life-sustaining therapy should automatically meet the criteria for the Disability Tax Credit and urges the Government to adopt this approach
JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, welcomes the release of the Disability Advisory Committee’s (DAC) Firs...Read More
EFFECTIVE DIABETES MANAGEMENT: Type 1 diabetes (T1D) strikes children and adults suddenly, and lasts a lifetime.
JDRF showcases advancements in T1D pregnancy care; highlighting JDRF CCTN and the CONCEPTT Trial, and exploring the challenges of managing T1D through pregnancy.
40 Kids and Country Superstar George Canyon Step up to Cure Type 1 Diabetes (T1D) JDRF Ambassadors head to Parliament Hill to discuss the importance of funding research
Lilly Canada provided JDRF with $220,000 in 2013-2014 in support of the creation of a national clinical training program to enable young investigators to further engage in medical research associated with type 1 diabetes.
Ability to produce embryonic stem cells will allow researchers to push faster toward cure
University of British Columbia, in collaboration with BetaLogics Venture, a division of Janssen Research & Development, LLC, has published a study highlighting a protocol to convert stem cells into insulin-producing cells. The new procedure could be an important step in the fight against Type 1 ...
Sun Life Financial and the Canadian Football League (CFL) partner to raise up to $100,000 for JDRF
JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate.
JDRF Partner ViaCyte Announces Key Project Milestone to Advance Innovative Encapsulated Cell Replacement Therapy Product for Type 1 Diabetes
To address the need for education on how patients with type 1 diabetes (T1D) can pursue physical activity safely, Novo Nordisk has committed to a three-year, $5 million grant in support of a new JDRF Outreach initiative titled “T1D Performance in Exercise and Know...